Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07546214 · ClinicalTrials.gov registry record · Phase 1
A Study Comparing Tapinarof Cream 1% and Vtama® Cream 1% in the Treatment of Plaque Psoriasis.
A Phase 1 study, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Phase 1
- Development phase
- 575
- Enrollment target
NCT07546214: Completed Phase 1 study, sponsored by Sun Pharmaceutical Industries.
NCT07546214 is a Phase 1 study that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 575 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (858% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07546214, a Phase 1 study, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 575 participants
- Enrollment target
Study Summary
To demonstrate therapeutic equivalence and safety of Tapinarof Cream, 1% (Sun pharma Canada, Inc.) and Vtama® (Tapinarof) Cream, 1% in the treatment of plaque psoriasis.
Primary Outcome
The proportion of subjects in each treatment group with treatment success with a minimum 2-grade improvement.
Interventions
- DRUG Placebo Control
- DRUG Tapinarof Cream, 1%
- DRUG Vtama® (Tapinarof) Cream, 1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 575 participants |
| Start Date | 2025-10-13 |
| Est. Completion | 2026-03-18 |
| Phase | Phase 1 |
What the finished NCT07546214 record still lists
NCT07546214 is an interventional study that assigns participants to a tested intervention. The registered 575 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (858% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo Control is the first listed.
NCT07546214 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07546214 about?
NCT07546214 is a clinical study titled "A Study Comparing Tapinarof Cream 1% and Vtama® Cream 1% in the Treatment of Plaque Psoriasis.". To demonstrate therapeutic equivalence and safety of Tapinarof Cream, 1% (Sun pharma Canada, Inc.) and Vtama® (Tapinarof) Cream, 1% in the treatment of plaque psoriasis.
What is the current status of trial NCT07546214?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 575 participants. The study started on 2025-10-13. Estimated completion is 2026-03-18.
What interventions are being tested in trial NCT07546214?
The interventions under investigation include: Placebo Control (DRUG), Tapinarof Cream, 1% (DRUG), Vtama® (Tapinarof) Cream, 1% (DRUG).
Who is sponsoring clinical trial NCT07546214?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07546214's enrollment target sits among peer trials
575 32nd of 2000 higher than 1,968 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02610439 · 575 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer
- NCT05919264 · 575 participants · Phase 1
FOG-001 in Locally Advanced or Metastatic Solid Tumors
- NCT06583148 · 575 participants · NA
A Smoke-Free Home Intervention in Tribal Communities
- NCT06883175 · 575 participants · NA
Evolution of the Chicago Classification: Bridging Physiology and Mechanics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI